Most Popular Papers *
Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials
Muhammad Ashar Ali
PARP Inhibitors for Treatment of BRCA1/2-Mutated Metastatic Breast Cancer- A Systematic Review and Meta-analysis
Ranju Kunwor, Daniel P. Silver, and Maysa Abu-Khalaf
Infectious complications and preventative strategies following Chimeric Antigen Receptor T-cells (CAR-T cells) therapy for B-cell malignancies
Alfadil Haroon, Ibrahim N. Muhsen, Muhammad Bilal Abid, Abdulwahab Albabtain, Ali Alahmari, Syed Osman Ahmed, Riad El Fakih, and Mahmoud Aljurf
Adoptive cellular therapy in acute myeloid leukemia: Current scope and challenges
Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, and Navneet S Majhail
JAK2/STAT5 pathway mutation frequencies in South African BCR/ABL negative MPN patients
Shires K, Rust A, Harryparsad R, Coburn J, and Gopie R
CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19
Yenny M. Vanegas, Razan Mohty, Martha E. Gadd, Yan Luo, Mahmoud Aljurf, Hong Qin, and Mohamed A. Kharfan-Dabaja
Understanding the etiology of pancytopenias in the CAR T-cell therapy setting: what we know and what we don’t?
Farah Yassine, Hemant Murthy, Emad Ghabashi, Mohamed A. Kharfan-Dabaja, and Madiha Iqbal
Next-Generation Chimeric Antigen Receptor T Cells
Dongni Yi, Mia Gergis, Jingmei Hsu, Yang Yang, Xia Bi, Mahmoud Aljurf, and Usama Gergis
Chimeric Antigen Receptor T-Cell Therapies in Lymphoma Patients with Central Nervous System Involvement
Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, and Usama Gergis
Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies
Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, and Usama Gergis
* Based on the average number of full-text downloads per day since the paper was posted.
» Updated as of 04/20/23.